GH1 and pituitary gland adenoma: Somatoprim, another second-generation SSA, is a multi-receptor targeting analog with a preference for SSTR2, SSTR4, and SSTR5, which was trialed in vitro on growth hormone (GH)-secreting pituitary adenomas.